ODAC backs Pfizer kidney cancer drug as second-line treatment
08 December 2011
Donna Young
Please Login to read the full article.
08 December 2011
Donna Young
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- Pfizer's Torisel fails in Phase III second-line kidney cancer trial
- NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
FEATURES
Other Informa Features
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
